WGSGeneDx Holdings Corp.
$67.31-48% 1Y
$67.31
$34.5152 weeks$167.51
WGS in its own filings
WGS's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
151
Events found in the filings · across 781 filings · the record starts in 2020
- Hard flags
- 4
Hard flags
- Most recent filing
- Aug 3, 2026
Most recent filing · Form 10-Q
- Record starts
- Aug 19, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 27, 2026
- Restatement admitted (non-reliance)3 occurrences
- 2022-03-14
- Change in certifying accountant2 occurrences
- 2021-08-16
- Late periodic reporthistorical
- 2021-05-18
- Delisting notice / listing-rule failurehistorical
- 2022-12-30
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2026-07-21
- SEC comment-letter activity24 occurrences
- 2025-07-30
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026GeneDx Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 16, 2026On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.Director or officer change · Form 8-K
- May 4, 2026GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook.Earnings release · press release
- Mar 2, 2026Loan Agreement On February 27, 2026 (the “Closing Date”), GeneDx Holdings Corp. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”), with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as …Material agreement entered · Form 8-K
- Sep 18, 2025On September 17, 2025, the Board of Directors (the “Board”) of GeneDx Holdings Corp., a Delaware corporation (the “Company”), appointed Thomas Fuchs, Dr.sc., effective immediately, as a Class I director on the Board with a term expiring at the Company’s 2028 Annual Meeting of Stockholders.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks
Diagnostics & Research
Ranks #9 of 21 by RyuScore